Key statistics
As of last trade, Abeona Therapeutics Inc (PCJ:FRA) traded at 4.14, 16.29% above the 52 week low of 3.56 set on Nov 07, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 4.14 |
|---|---|
| High | 4.14 |
| Low | 4.14 |
| Bid | 4.14 |
| Offer | 4.32 |
| Previous close | 4.10 |
| Average volume | 132.57 |
|---|---|
| Shares outstanding | 54.19m |
| Free float | 46.73m |
| P/E (TTM) | 4.53 |
| Market cap | 271.50m USD |
| EPS (TTM) | 1.11 USD |
Data delayed at least 15 minutes, as of Feb 16 2026 07:17 GMT.
More ▼
Announcements
- Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer
- Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas
- Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy
- Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates
- Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation
- Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)
More ▼
